Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study

Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study

Item

http://www.wikidata.org/entity/Q28293377

Q28293377

about

Venous thromboembolic disease A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Treating venous thromboembolism in patients with cancer.Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit Prevention of venous thromboembolism in hospitalized medical cancer patients: guidance from the SSC of the ISTH.Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis.An update on heparin-induced thrombocytopenia: diagnosis and management.Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.Evidence-based guidance on venous thromboembolism in patients with solid tumours Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].Bilateral spontaneous, simultaneous lower extremity hematomas in a patient on dalteparin.Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment.Dosing low molecular weight heparins in kidney disease.Deep vein thrombosis and stress ulcer prophylaxis in the intensive care unit.A review of venous thromboembolism prophylaxis for hospitalized medical patients.Considerations for Systemic Anticoagulation in ESRD.Venous thromboembolism in cancer patients: risk assessment, prevention and management.Preferences in traumatic intracranial hemorrhage: bleeding vs. clotting.Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?Renal function and thromboprophylaxis in critically ill patients Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our Preconceptions.Serious adverse events in academic critical care research.Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.Physicians declining patient enrollment in a critical care trial: a case study in thromboprophylaxis.Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study.Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial.Association Between Low-Molecular-Weight Heparin and Risk of Bleeding Among Hemodialysis Patients: A Retrospective Cohort Study

P2860

Q24631121-FCF086B3-E83B-435A-AA74-5B234ED3FBAD Q26995027-5F4B1966-1AEA-4EDE-91E6-922E5F5362CE Q33399576-4D8B7CC8-FD4E-432B-AE74-F34DC5DA786F Q33400564-E8B8CA88-BCA5-4FC4-92BB-BEA9E5B40127 Q33414888-7C89C9B7-4808-4C0D-92A9-7B63D31C8B39 Q33416926-24FD1F7B-1298-40B4-B832-E3EDB1BF2B40 Q33420469-4BF61877-1C56-49AD-A687-5D5030D77B8B Q33422297-5D3B038F-A2FB-4C65-B06B-906B1FB0DCCD Q33430644-E80370A2-D624-42C5-9050-BA6096B3116A Q33442494-264EE3A1-FF91-4ECF-9EC3-895439E8B752 Q33763946-3084D974-D0BF-46EF-AD48-EC23BD09CAC4 Q35851245-674C5726-D126-431D-9A13-C4FAD4F6CDD9 Q37385500-027ED60F-809F-4919-908B-72942046EABC Q37490581-51605A94-DAB1-433F-927D-46061033453F Q37844143-EAAAF737-5E46-41CE-85A0-29F6A33ADC2E Q37867276-5F19175F-6E2A-4587-83B2-88CE667A0C30 Q37867319-9901FE50-DA92-4AF8-9DA8-5D32C725C020 Q38129188-8180D1F1-4FD2-43B3-A91F-500E9A103F5F Q38464975-B99CF704-11C0-47B5-85F6-9A53489EBF79 Q38751462-99F22F28-4CD2-4D02-A594-9731698BA4FD Q39870252-7CD67162-B1EC-4430-AEBB-BD6467F673DB Q41227272-B40A4ADD-3DE5-4673-81DD-04CB931B2333 Q41959528-C558C437-27CC-4715-8B2B-C2E5B9957D86 Q43077281-DC578E62-8A3D-489A-B368-426C7288E31C Q43112082-3A82E81A-C57A-4619-AE98-1491FA00498A Q44316500-7400B19F-0462-44A5-B191-C85F8AA7087F Q44681764-5DC3B041-DF49-47F1-9481-5EEE87183834 Q50981591-0261BF28-B5F8-4B4D-9273-D16DA1BC33C5 Q55256572-C5821AF0-0109-4614-9412-DE1211B5C51E Q58803291-0316AF5A-FD35-4885-8453-1A9DCB36076F

P2860

Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study

Item

http://www.wikidata.org/entity/Q28293377

description

2008 nî lūn-bûn

@nan

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu